Story · Medicine & Biotech

Zipalertinib Plus Chemotherapy Moves Toward FDA Review After Six-Month PFS Benefit in EGFR Exon 20 Insertion-Mutated Lung Cancer

1 outlet · first reported by OncoDaily on

A new targeted treatment combination for a difficult-to-treat subtype of lung cancer has reached an important regulatory milestone. Cullinan Therapeutics announced on November 12, 2026, that its partner, Taiho Oncology, (OncoDaily)

Coverage, in order

  1. OncoDaily obscure study
    Zipalertinib Plus Chemotherapy Moves Toward FDA Review After Six-Month PFS Benefit in EGFR Exon 20 Insertion-Mutated Lung Cancer

    A new targeted treatment combination for a difficult-to-treat subtype of lung cancer has reached an important regulatory milestone. Cullinan Therapeutics announced on November 12, 2026, that its partner, Taiho Oncology,

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.